– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in…
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training…
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of…
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American…
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data…
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II…
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on…
Partnership to enable cancer care centers to improve access and efficiency of clinical studies and researchNEW YORK--(BUSINESS WIRE)--Flatiron Health, a…